Clinical trial
Efficacy of the New Closure Device in Improving Patient Compliance in Treatment…
NCT00487123 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00487123 |
|---|---|
| Title | Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months |
| Official title | A Multi-Center, Randomized, Proof-of-Concept, Parallel Control Study With Remind Cap® in Patients With Essential Hypertension and Newly Treated With Valsartan+/-Hydrochlorothiazide (HCTZ) |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Valsartan+/- Hydrochlorothiazide |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Jun 15, 2007 |
| Last update posted | Jun 17, 2008 |
| Countries | Singapore |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: